These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 9749450)

  • 1. A framework establishing clear decision criteria for the assessment of drug efficacy.
    Huster WJ; Enas GG
    Stat Med; 1998 Aug 15-30; 17(15-16):1829-38. PubMed ID: 9749450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Providing evidence of efficacy for a new drug.
    Ruberg S; Cairns V
    Stat Med; 1998 Aug 15-30; 17(15-16):1813-23; discussion 1825-7. PubMed ID: 9749449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The management of interim analyses in drug development.
    Facey KM; Lewis JA
    Stat Med; 1998 Aug 15-30; 17(15-16):1801-9; discussion 1811-2. PubMed ID: 9749448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Methodological recommendations of the Regulatory Agencies].
    Torres F; Calvo G; Pontes C
    Med Clin (Barc); 2005 Dec; 125 Suppl 1():72-6. PubMed ID: 16464431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
    Chilcott J; Tappenden P; Rawdin A; Johnson M; Kaltenthaler E; Paisley S; Papaioannou D; Shippam A
    Health Technol Assess; 2010 May; 14(25):iii-iv, ix-xii, 1-107. PubMed ID: 20501062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practical issues in equivalence trials.
    Ebbutt AF; Frith L
    Stat Med; 1998 Aug 15-30; 17(15-16):1691-701. PubMed ID: 9749440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report.
    Ramsey S; Willke R; Briggs A; Brown R; Buxton M; Chawla A; Cook J; Glick H; Liljas B; Petitti D; Reed S
    Value Health; 2005; 8(5):521-33. PubMed ID: 16176491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 'Is this treatment worth while?' How to read the medical journals.
    Rheeder P; Ker JA
    S Afr Med J; 2000 Jan; 90(1):37-9. PubMed ID: 10721386
    [No Abstract]   [Full Text] [Related]  

  • 14. International Conference on Harmonisation; choice of control group and related issues in clinical trials; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2001 May; 66(93):24390-1. PubMed ID: 12356096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seeking harmony: estimands and sensitivity analyses for confirmatory clinical trials.
    Mehrotra DV; Hemmings RJ; Russek-Cohen E;
    Clin Trials; 2016 Aug; 13(4):456-8. PubMed ID: 26908545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of compliance of European Public Assessment Reports to guidelines for paediatric drug development before the introduction of paediatric investigation plans.
    Piana C; Kliphuis E; Della Pasqua O
    Clin Trials; 2013 Apr; 10(2):269-79. PubMed ID: 23335676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methodological advances and plans for improving regulatory success for confirmatory studies.
    Koch GG; Davis SM; Anderson RL
    Stat Med; 1998 Aug 15-30; 17(15-16):1675-90. PubMed ID: 9749439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence.
    Siebert U; Rochau U; Claxton K
    Z Evid Fortbild Qual Gesundhwes; 2013; 107(9-10):575-84. PubMed ID: 24315327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials.
    Marchetti S; Schellens JH
    Br J Cancer; 2007 Sep; 97(5):577-81. PubMed ID: 17726450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Applying Bayesian ideas in drug development and clinical trials.
    Spiegelhalter DJ; Freedman LS; Parmar MK
    Stat Med; 1993 Aug; 12(15-16):1501-11; discussion 1513-7. PubMed ID: 8248659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.